National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Carfilzomib (Kyprolis®) in combination with dexamethasone (CAR+DEX).

Carfilzomib (Kyprolis®) is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

 

NCPE Assessment Process Complete
Rapid review commissioned 11/02/2019
Rapid review completed 19/03/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of carfilzomib in combination with dexamethasone compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

 

The HSE has approved reimbursement following confidential price negotiations; October 2020